Alexandria Real Estate Equities enters the back half of August with its sharpest options skew in months, a stock price near its lowest level in the recent slide, and a founder quietly buying into the weakness — a setup that leaves bulls and bears reading the same data very differently.
The clearest signal this week is in options. Defensive demand has jumped sharply, with the put/call ratio climbing to 1.23 — nearly two standard deviations above its 20-day average of 1.04. That's the most bearishly skewed reading in several months, though still well below the 52-week peak of 1.72. The move comes as the stock dropped 4.7% over the past week to close at $45.84, extending a one-month decline of nearly 9%. Options traders have been rotating toward protection since early August, when the PCR was running below 0.93 — the shift in direction is as notable as the absolute level.
Short interest tells a less defensive story than options do. Bears have actually been retreating. SI fell 12.5% over the past week to around 4.1% of free float — a level that is modest by any standard and still easing. Borrow conditions reinforce the same message: cost to borrow has slipped further to just 0.37%, and availability is exceptionally loose at over 2,100% of outstanding short interest, meaning there is no meaningful constraint on either side of the lending market. The ORTEX short score has drifted lower all week, from 42.5 on August 10 to 39.8 as of Tuesday — positioning that looks cautious rather than crowded on the short side.
The Street is broadly constructive but trimming targets after what was a difficult earnings cycle. Evercore ISI's Steve Sakwa reiterated his Outperform rating this week but cut his target to $57 from $59 — the second reduction in roughly two weeks, following an earlier trim from $60. Citigroup raised its Neutral target to $50 from $42, and Cantor Fitzgerald moved to $52 from $43, both keeping neutral ratings but acknowledging improved valuation entry points. The mean analyst target of $52 implies about 13% upside from current levels. One notable outlier remains BNP Paribas, which carries an Underperform with a $48 target — currently above the stock price — while Morgan Stanley downgraded to Underweight in June, holding a $53 target. The bull case centres on ARE's differentiated life-science laboratory portfolio and construction pipeline strength. Bears point to near-term occupancy headwinds, asset sales to fund development, and a forecast for core earnings to fall roughly 28% in 2026. The price-to-book ratio has compressed to 0.49, reflecting how deeply the market has already re-rated the stock.
The most genuinely interesting data point in the ownership picture is founder-level buying in May. Executive Chairman Joel Marcus purchased approximately 25,000 shares across five separate transactions between May 4 and May 6, paying $41–$47 per share — levels close to where the stock trades today. Those buys totalled around $1.1 million and carried a significance score of 3, the highest in the recent insider history. Against that, CEO Peter Moglia and CFO Marc Binda have been making smaller, routine sales. BlackRock added just over 2 million shares in its most recent filing, and State Street added 410,000 — both modest additions from large passive holders. The net 90-day insider position is a positive 30,000 shares, driven almost entirely by Marcus's cluster purchase. It is at least consistent with a view that near current prices, the founder sees value.
Post-earnings history adds context. ARE has dropped around 5% the day after each of the two most recent quarterly prints, and extended those losses to roughly 6–9% over the following week. The next earnings event is scheduled for October 19, and given the pattern, options traders positioning defensively now — even two months out — may be anchoring to that experience. With SI falling, borrow loose, and the founder having bought into the last dip near these levels, what to watch next is whether the options skew continues to widen or begins to normalise as the stock finds footing around the $45 range that attracted insider interest three months ago.
See the live data behind this article on ORTEX.
Open ARE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
